Skip to main content
Publications
Rebordosa C , Thomsen RW, Tave AK, Madsen M, Beachler DC, Martinez D , Garcia-Esteban R , Plana E , Tormos A , Farsani SF, Perez-Gutthann S , Pladevall-Vila M . Liver, renal, genitourinary, and diabetic ketoacidosis risks among new users of empagliflozin versus DPP-4 inhibitors in patients with type 2 diabetes: post-authorisation safety study based on multinational cohorts . Diabetes Obes Metab. 2024 Apr;26(4):1291-304. doi: 10.1111/dom.15429
Saigi-Morgui N , Quteineh L, Bochud PY, Crettol S, Kutalik Z, Mueller NJ, Binet I, Van Delden C, Steiger J, Mohacsi P, Dufour JF, Soccal PM, Pascual M, Eap CB, Swiss Cohort Study. Genetic and clinic predictors of new onset diabetes mellitus after transplantation . Pharmacogenomics J. 2019 Feb;19(1):53-64. doi: 10.1038/s41397-017-0001-5
Samelson EJ, Miller PD, Christiansen C, Daizedeh NS, Grazette L, Anthony MS , Egbuna O, Wang A, Siddhanti SR, Cheung AM, Franchimont N, Kiel DP. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk . J Bone Miner Res. 2014 Feb;29(2):450-7. doi: 10.1002/jbmr.2043